The Filing Desk

Nutex Health

NUTX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

NUTX · Last close · November 13, 2026
$173.67
Value Nutex Health yourself

Nutex Health's revenue rose 82.4% to $875 million in fiscal 2025. Its operating margin was 31.5%, up from 27.2% a year earlier. Free cash flow was $246 million, up 1078.0%. It paid out $5 million in dividends and buybacks, 2% of free cash flow. The diluted share count rose 23.0%.

NUTEX HEALTH INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001628280-26-015168 Updated
Revenue
$875M
82.4%
Operating margin
31.5%
4.3 pts
Net income
$71M
35.9%
Free cash flow
$246M
1078.0%
Return on capital
40.3%
10.8 pts
Market cap
$1.2B
Nov 13 close
P/E
7.5x
On $23.22 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Nutex Health does

Nutex Health is a healthcare company based in Houston, run by doctors. At the end of 2025 it owned and ran 26 hospital facilities in 12 states, with nine more micro-hospitals in development. Micro-hospitals are small hospitals with emergency rooms, a few inpatient beds and on-site imaging, labs and pharmacy. It has 944 full-time employees and contracts more than 280 doctors at its facilities.

It reports three segments. The hospital division builds and runs micro-hospitals, specialty hospitals and hospital outpatient departments, and provides emergency, inpatient and behavioral health care. Most of its hospitals are out-of-network with insurers, which means they do not have negotiated rates with most insurance companies. The population health division owns and runs provider networks, such as independent physician associations, that take on the financial risk of caring for groups of patients. The real estate division holds property used by its hospitals.

Nutex gets paid for patient care by insurers, government programs and patients. It also runs the business side for each hospital, including billing, staffing and compliance. Most hospitals have contracts with separately owned doctor groups and property companies, some owned in part by its chairman and chief executive. Nutex says it expects to contract directly with more commercial insurers in the future.

Its biggest risks, as it describes them

  • Uncertainty and lawsuits over the No Surprises Act's payment dispute process, which may cut cash it collects.
  • Relying on an outside company, HaloMD, in that dispute process, and having no right to audit its data.
  • Being mostly out of network with insurers, so it has no negotiated payment rates with most of them.
  • Issuing more shares to former doctor owners of new hospitals, which would dilute current shareholders.
  • Write-offs or impairment charges, and past weaknesses in its financial reporting controls.
From Nutex Health's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2025, earnings per share grew 138.5% a year and net income 81.5% a year, as buybacks cut the share count by 92%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments36342241186
Debt incl. finance leases156243255304318
Net debt (negative means net cash)120209233263133
Net debt to EBITDA0.7x——1.8x0.5x
Debt to equity1.4x2.5x4.2x2.3x1.0x
Interest coverage27.5x−32.5x−1.9x6.6x12.4x
Current ratio4.1x1.8x1.6x1.9x3.4x
Quick ratio4.0x1.7x1.5x1.9x3.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Nutex Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Nutex Health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 97 of 97 of 9
Rule of 409.6%98.2%110.4%
Altman Z''−3.091.374.62
Accruals ratio−11.3%5.5%−22.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assetsFailPassPass
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score5 of 97 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Nutex Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Nutex HealthFY2582.4%31.5%28.1%40.3%0.5x7
U.S. Physical TherapyFY2516.3%11.1%7.8%10.7%1.2x6Compare
National HealthcareFY2516.1%8.5%9.8%9.4%−0.3x6Compare
Sonida Senior LivingFY2525.2%—−2.3%−3.8%29.2x3Compare
Astrana HealthFY2556.4%2.5%3.3%4.2%4.9x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0011274332219248480875
Revenue growth−100.0%—5,800.9%−0.0%19,954.5%21.0%−33.9%12.9%93.8%82.4%
Gross profit0−0101581791535196444
Research and development——0110————
Operating income−0−6−1−7153170−407−32131276
Net income−71−1−7106133−425−465271
Diluted EPS (US$)−0.190.01−0.56−1.960.180.22−100.36−10.399.6910.48
Diluted shares (millions)40842455934467
Cash flow
Cash from operations−0−1−0−48717351123248
Capital expenditure——006137151022
Free cash flow——−0−42513736−821246
Dividends paid0000000000
Share buybacks0000000005
Acquisitions0000000100
Stock-based compensation0100340—−0108
Balance sheet at fiscal year end
Cash and short-term investments0001036342241186
Debt incl. finance leases——000156243255304318
Total assets03070395432398655918
Total liabilities64251203311319467495
Shareholders' equity−6−1−22−11159662132329
Margins and ratios
Gross margin—−31.6%62.9%39.2%57.5%54.1%7.0%14.0%40.9%50.8%
Operating margin—−24,574.5%−61.5%−504.8%55.9%51.4%−185.4%−12.8%27.2%31.5%
Net margin—2,512.6%−69.5%−520.8%38.7%40.0%−193.7%−18.5%10.8%8.1%
Free cash flow margin——−35.1%−301.9%9.3%41.2%16.4%−3.3%4.3%28.1%
Rule of 40 (growth + FCF margin)——5,765.8%−301.9%19,963.8%62.2%−17.4%9.6%98.2%110.4%
Return on capital———−22.5%155.2%73.8%−100.2%−7.8%29.5%40.3%
Return on equity———−3,941.8%29,247.7%233.6%−403.6%−58.2%53.7%30.6%
Return on assets−182.4%30.3%−50.3%−199.3%3,088.4%67.2%−102.8%−11.0%9.9%9.0%
Net debt to EBITDA————−0.0x0.7x——1.8x0.5x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Nutex Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Nutex Health.